Global Hepatitis B Infection Market
Размер рынка в млрд долларов США
CAGR :
% 
 Прогнозируемый период |
2024 –2031 |
 Размер рынка (базовый год) |
USD 12.11 Billion |
 Размер рынка (прогнозируемый год) |
USD 18.21 Billion |
 CAGR |
% |
| Основные игроки рынка |
Global Hepatitis B Infection Market, By Type (Chronic and Acute), By treatment (Vaccine, Antiviral Drugs, Immune Modulator Drugs, and Surgery - Industry Trends and Forecast to 2031
Hepatitis B Infection Market Analysis and Insights
Data Bridge Market Research analyzes that the global hepatitis B infection market is expected to reach USD 18.21 billion by 2031 from USD 12.11 billion in 2023, growing with a CAGR of 5.2% in the forecast period of 2024 to 2031.
|
Report Metric |
Details |
|
Forecast Period |
2024 to 2031 |
|
Base Year |
2023 |
|
Historic Years |
2022 (Customizable to 2016–2021) |
|
Quantitative Units |
Revenue in USD Billion |
|
Segments Covered |
Type (Chronic and Acute), Treatment (Vaccine, Antiviral Drugs, Immune Modulator Drugs, and Surgery |
|
Countries Covered |
U.S., Canada and Mexico, China, India, Japan, South Korea, Singapore, Thailand, Malaysia, Indonesia, Australia, Vietnam, New Zealand, Taiwan, Philippines, and rest of Asia-Pacific, Germany, U.K., France, Italy, Spain, Russia, Netherlands, Switzerland, Belgium, Sweden, Denmark, Norway, Finland, Poland Turkey, and rest of Europe, South Africa, Saudi Arabia, Egypt, Kuwait, Qatar, U.A.E., Oman, Bahrain, and rest of Middle east and Africa, Brazil, Argentina, and rest of South America |
|
Market Players Covered |
Gilead Sciences, Inc. (U.S.), GlaxoSmithKline plc (UK), Dynavax Technologies (U.S.), F. Hoffmann-La Roche Ltd (Switzerland), Bristol-Myers Squibb Company (U.S.), Merck Sharp and Dohme Corp. (U.S.), Novartis AG (Switzerland), Arrowhead Pharmaceuticals Inc. (U.S.), Arbutus Biopharma (Canada), Teva Pharmaceuticals, Inc. (Israel), Zydus Pharmaceuticals (India), Aurobindo Pharma (India), Lupin Pharmaceuticals, Inc. (India) |
Market Definition
The global hepatitis B infection market refers to the healthcare sector focused on the diagnosis, treatment, prevention, and management of hepatitis B virus (HBV) infections. This market encompasses a wide range of products and services, including vaccines, antiviral drugs, diagnostic tests, immune modulators, and therapeutics aimed at addressing both acute and chronic forms of hepatitis B. Hepatitis B is a highly infectious liver disease caused by the HBV, which can lead to severe health complications like cirrhosis, liver failure, and hepatocellular carcinoma. The market includes pharmaceutical companies, biotechnology firms, diagnostic service providers, healthcare facilities, and research institutions working to develop advanced treatment solutions. The increasing prevalence of hepatitis B globally, coupled with rising awareness and government initiatives to curb its spread, are key drivers of market growth.
Global Hepatitis B Infection Market Dynamics.
This section deals with understanding the market drivers, opportunities, restraints, and challenges. All of this is discussed in detail below:
Drivers
- increasing Prevalence of Hepatitis B Infections
The increasing prevalence of Hepatitis B infections serves as a significant driver in the global Hepatitis B infection market by creating a growing demand for effective diagnostic tools, vaccines, and antiviral treatments. As Hepatitis B is a major cause of liver diseases such as cirrhosis and liver cancer, the rising infection rates globally, particularly in regions with inadequate healthcare infrastructure, have heightened the need for prevention, management, and treatment options. The spread of chronic Hepatitis B infections, especially in low- and middle-income countries where awareness and vaccination programs are less established, further amplifies the market for immunization, antiviral therapies, and advanced diagnostic techniques. Also, pharmaceutical companies are investing in research and development of newer, more efficient antiviral drugs and vaccines to address the evolving strains of the virus. The rise in both acute and chronic cases, particularly in high-risk populations, has put pressure on healthcare systems to invest in improved diagnostics, vaccines, and antiviral therapies.
Restraints
- Side effects and drug resistance
- Side effects and drug resistance serve as significant restraints in the global Hepatitis B infection market by limiting the effectiveness and long-term use of available therapies. Many antiviral drugs used to treat Hepatitis B can cause adverse effects such as fatigue, nausea, liver toxicity, and kidney damage, which can lead to poor patient adherence and treatment discontinuation. This not only hampers the success of treatment but also reduces the overall demand for certain medications. Furthermore, the development of drug-resistant strains of the Hepatitis B virus presents another major challenge, as it reduces the efficacy of current antiviral therapies and necessitates the constant development of new drugs. As resistance to existing treatments increases, it creates barriers for healthcare providers in managing the infection effectively, limiting the market's growth potential. These challenges contribute to hesitancy in prescribing long-term antiviral therapies, slowing the adoption of certain medications and thereby restraining market expansion
Opportunity
- Rising New Drug Releases and Increasing New Drug Permits for Hepatitis B
The hepatitis B market is experiencing significant growth, driven by several key factors including the rising number of new drug releases and an increase in new drug permits. The surge in drug approvals is partly a response to the persistent need for more effective antiviral therapies and vaccines to manage and potentially eradicate hepatitis B. This trend is evident from the increased investments in research and development by major pharmaceutical companies, which are focusing on innovative treatment options that offer improved efficacy, fewer side effects, and enhanced patient compliance. Additionally, advancements in drug delivery systems and the development of combination therapies have contributed to the expansion of the market. The growth in market share for hepatitis B drugs is also supported by the increasing global prevalence of the disease, particularly in regions with high infection rates such as Asia-Pacific and sub-Saharan Africa. As new therapies become available and the market becomes more competitive, financial growth is expected to be robust, with projections indicating a substantial increase in market value over the coming years. This growth is underpinned by rising healthcare expenditure, broader healthcare access, and heightened awareness about the importance of hepatitis B management. The market is likely to see continued expansion as new players enter the field, existing companies innovate, and healthcare systems around the world prioritize hepatitis B treatment.
Challenge
- The Cost of Hepatitis B Treatments is High
The high cost of hepatitis B treatments presents significant challenges for the market. One of the primary factors contributing to this challenge is the complexity of developing antiviral drugs and immunomodulators that effectively manage the virus without causing severe side effects. This complexity requires extensive research, clinical trials, and regulatory approvals, all of which drive up the price of the final product. Additionally, the ongoing nature of treatment for chronic hepatitis B means that patients often face long-term costs, which can be prohibitively expensive, particularly in regions with limited access to healthcare subsidies or insurance coverage.
Another challenge is the limited availability of generic versions of hepatitis B drugs. Many of the more effective treatments remain under patent protection, allowing pharmaceutical companies to maintain high prices. This lack of competition further exacerbates the financial burden on patients, healthcare systems, and governments. Moreover, the development of newer treatments, such as those aimed at complete viral eradication, is still in the early stages, with no immediate prospects for significantly lowering treatment costs in the near future.
- In May 2022, according to the article published by the Hepatitis B Foundation , the estimated 300 million people living with hepatitis B, only 10% have been diagnosed, and just 22% of those diagnosed receive antiviral treatments. In Africa, the situation is even more dire, with only 2% of individuals with chronic hepatitis B receiving a diagnosis and just 0.1% receiving treatment. A significant barrier to treatment is the cost
Recent Developments
- In September 2024, Gilead Sciences and Genesis Therapeutics announced a strategic collaboration to discover and develop novel small molecule therapies using Genesis’ GEMS AI platform. Gilead gained exclusive rights to develop and commercialize products from this partnership
- In February 2024, GSK completed its acquisition of Aiolos Bio, including the promising AIO-001 monoclonal antibody for severe asthma. GSK paid USD 1000 million upfront and up to USD 400 million in milestone payments, expanding its respiratory biologics portfolio
Global Hepatitis B Infection Market Scope
Global hepatitis B infection market is categorized into two notable segments which are based on the type and treatment. The growth among segments helps you analyze niche pockets of growth and strategies to approach the market and determine your core application areas and the differences in your target markets.
Type
- Chronic
- Acute
On the basis of type, market is segmented into chronic and acute.
Treatment
- Vaccine
- Antiviral Drugs
- Immune Modulator Drugs
- Surgery
On the basis of treatment, market is segmented into vaccine, antiviral drugs, immune modulator drugs, and surgery.
Global Hepatitis B Infection Market Regional Analysis/Insights
Global hepatitis B infection market is categorized into two notable segments which are based on the type and treatment.
The country covered in this market report are U.S., Canada and Mexico, China, India, Japan, South Korea, Singapore, Thailand, Malaysia, Indonesia, Australia, Vietnam, New Zealand, Taiwan, Philippines, and rest of Asia-Pacific, Germany, U.K., France, Italy, Spain, Russia, Netherlands, Switzerland, Belgium, Sweden, Denmark, Norway, Finland, Poland Turkey, and rest of Europe, South Africa, Saudi Arabia, Egypt, Kuwait, Qatar, U.A.E., Oman, Bahrain, and rest of Middle east and Africa, Brazil, Argentina, and rest of South America.
Asia-Pacific is expected to dominate the market due to development of combination therapies for hepatitis B and strategic initiatives by companies for hepatitis B infection.
The country section of the report also provides individual market-impacting factors and changes in regulation in the market domestically that impact the current and future trends of the market. Data points such as new sales, replacement sales, country demographics, regulatory acts, and import-export tariffs are some of the major pointers used to forecast the market scenario for individual countries. Also, the presence and availability of global brands and their challenges faced due to large or scarce competition from local and domestic brands and the impact of sales channels are considered while providing forecast analysis of the country data.
Competitive Landscape and Global Hepatitis B Infection Market Dynamics Share Analysis
Global hepatitis B infection market dynamics market competitive landscape provides details of competitors. Details included are company overview, company financials, revenue generated, market potential, investment in R&D, new market initiatives, production sites and facilities, company strengths and weaknesses, product launch, product approvals, product width and breadth, application dominance, and product type lifeline curve. The above data points provided are only related to the company’s focus on the market.
Some of the major market players operating in the market are Gilead Sciences, Inc. (U.S.), GlaxoSmithKline plc (UK), Dynavax Technologies (U.S.), F. Hoffmann-La Roche Ltd (Switzerland), Bristol-Myers Squibb Company (U.S.), Merck Sharp and Dohme Corp. (U.S.), Novartis AG (Switzerland), Arrowhead Pharmaceuticals Inc. (U.S.), Arbutus Biopharma (Canada), Teva Pharmaceuticals, Inc. (Israel), Zydus Pharmaceuticals (India), Aurobindo Pharma (India), Lupin Pharmaceuticals, Inc. (India).
SKU-
Get online access to the report on the World's First Market Intelligence Cloud
- Интерактивная панель анализа данных
- Панель анализа компании для возможностей с высоким потенциалом роста
- Доступ аналитика-исследователя для настройки и запросов
- Анализ конкурентов с помощью интерактивной панели
- Последние новости, обновления и анализ тенденций
- Используйте возможности сравнительного анализа для комплексного отслеживания конкурентов
Содержание
1 INTRODUCTION
1.1 OBJECTIVES OF THE STUDY
1.2 MARKET DEFINITION
1.3 OVERVIEW OF GLOBAL HEPATITIS B INFECTION MARKET
1.4 MARKETS COVERED
2 MARKET SEGMENTATION
2.1 MARKETS COVERED
2.2 GEOGRAPHICAL SCOPE
2.3 YEARS CONSIDERED FOR THE STUDY
2.4 CURRENCY AND PRICING
2.5 DBMR TRIPOD DATA VALIDATION MODEL
2.6 MULTIVARIATE MODELLING
2.7 THERAPEUTICS LIFELINE CURVE
2.8 PRIMARY INTERVIEWS WITH KEY OPINION LEADERS
2.9 DBMR MARKET POSITION GRID
2.1 VENDOR SHARE ANALYSIS
2.11 SECONDARY SOURCES
2.12 ASSUMPTIONS
3 EXECUTIVE SUMMARY
4 PREMIUM INSIGHT
4.1 PESTAL ANALYSIS
4.2 PORTER FIVE FORCES
5 GLOBAL HEPATITIS B INFECTION MARKET: REGULATIONS
5.1 REGULATORY AUTHORITIES IN THE ASIA-PACIFIC REGION
5.2 NORTH AMERICA REGULATORY SCENARIO
5.3 EUROPE REGULATORY SCENARIO
5.4 MIDDLE EAST AND AFRICA REGULATORY SCENARIO
5.5 SOUTH AMERICA REGULATORY SCENARIO
6 PIPELINE ANALYSIS
7 EPIDEMILIOGY
8 MARKET OVERVIEW
8.1 DRIVERS
8.1.1 INCREASING PREVALENCE OF HEPATITIS B INFECTIONS
8.1.2 TECHNOLOGICAL ADVANCEMENTS IN DIAGNOSTICS
8.1.3 DEVELOPMENT OF COMBINATION THERAPIES FOR HEPATITIS B
8.1.4 STRATEGIC INITIATIVES BY COMPANIES FOR HEPATITIS B INFECTION
8.2 RESTRAINTS
8.2.1 SIDE EFFECTS AND DRUG RESISTANCE
8.2.2 INSUFFICIENT VACCINE COVERAGE FOR HEPATITIS B INFECTION
8.3 OPPORTUNITY
8.3.1 RISING NEW DRUG RELEASES AND INCREASING NEW DRUG PERMITS FOR HEPATITIS B
8.3.2 GOVERNMENT PROGRAMS TO RAISE AWARENESS OF HEPATITIS B INFECTION
8.3.3 ADVANCED RESEARCH AND DEVELOPMENT FOR CLINICAL TRIALS
8.4 CHALLENGES
8.4.1 THE COST OF HEPATITIS B TREATMENTS IS HIGH
8.4.2 STRINGENT REGULATORY POLICIES AND REGIONAL DISPARITIES IN TREATMENT ACCESS
9 GLOBAL HEPATITIS B INFECTION MARKET, BY TYPE
9.1 OVERVIEW
9.2 CHRONIC
9.3 ACUTE
10 GLOBAL HEPATITIS B INFECTION MARKET, BY TREATMENT
10.1 OVERVIEW
10.2 VACCINE
10.2.1 HOSPITAL PHARMACIES
10.2.2 DRUGS STORES AND RETAIL PHARMACIES
10.2.3 ONLINE PHARMACIES
10.3 ANTIVIRAL DRUGS
10.3.1 TENOFOVIR ALAFENAMIDE FUMARATE (TAF)
10.3.2 TENOFOVIR DISOPROXIL FUMARATE (TDF)
10.3.3 ENTECAVIR
10.3.4 OTHERS
10.4 IMMUNE MODULATOR DRUGS
10.4.1 PEGYLATED INTERFERON
10.4.2 INTERFERON ALPHA
10.5 SURGERY
11 GLOBAL HEPATITIS B INFECTION MARKET, BY REGION
11.1 OVERVIEW
11.2 NORTH AMERICA
11.2.1 U.S
11.2.2 CANADA
11.2.3 MEXICO
11.3 SOUTH AMERICA
11.3.1 BRAZIL
11.3.2 ARGENTINA
11.3.3 REST OF SOUTH AMERICA
11.4 MIDDLE EAST AND AFRICA
11.4.1 SOUTH AFRICA
11.4.2 SAUDI ARABIA
11.4.3 EGYPT
11.4.4 KUWAIT
11.4.5 QATAR
11.4.6 U.A.E
11.4.7 OMAN
11.4.8 BAHRAIN
11.4.9 REST OF MIDDLE EAST AND AFRICA
11.5 ASIA-PACIFIC
11.5.1 CHINA
11.5.2 INDIA
11.5.3 INDONESIA
11.5.4 JAPAN
11.5.5 VIETNAM
11.5.6 PHILIPPINES
11.5.7 THAILAND
11.5.8 SOUTH KOREA
11.5.9 AUSTRALIA
11.5.10 SINGAPORE
11.5.11 MALAYSIA
11.5.12 NEW ZEALAND
11.5.13 TAIWAN
11.5.14 REST OF ASIA-PACIFIC
11.6 EUROPE
11.6.1 GERMANY
11.6.2 U.K
11.6.3 TURKEY
11.6.4 RUSSIA
11.6.5 SPAIN
11.6.6 ITALY
11.6.7 SWEDEN
11.6.8 BELGIUM
11.6.9 POLAND
11.6.10 FRANCE
11.6.11 SWITZERLAND
11.6.12 NETHERLANDS
11.6.13 NORWAY
11.6.14 DENMARK
11.6.15 FINLAND
11.6.16 REST OF EUROPE
12 GLOBAL HEPATITIS B TREATMENT MARKET: COMPANY LANDSCAPE
12.1 COMPANY SHARE ANALYSIS: GLOBAL
12.2 COMPANY SHARE ANALYSIS: NORTH AMERICA
12.3 COMPANY SHARE ANALYSIS: EUROPE
12.4 COMPANY SHARE ANALYSIS: ASIA - PACIFIC
13 SWOT ANALYSIS
14 COMPANY PROFILE
14.1 GILEAD SCIENCES, INC.
14.1.1 COMPANY SNAPSHOT
14.1.2 REVENUE ANALYSIS
14.1.3 COMPANY SHARE ANALYSIS
14.1.4 PRODUCT PORTFOLIO
14.1.5 RECENT DEVELOPMENT
14.2 GLAXOSMITHKLINE PLC
14.2.1 COMPANY SNAPSHOT
14.2.2 REVENUE ANALYSIS
14.2.3 COMPANY SHARE ANALYSIS
14.2.4 PRODUCT PORTFOLIO
14.2.5 RECENT DEVELOPMENT
14.3 DYNAVAX TECHNOLOGIES CORPORATION
14.3.1 COMPANY SNAPSHOT
14.3.2 REVENUE ANALYSIS
14.3.3 COMPANY SHARE ANALYSIS
14.3.4 PRODUCT PORTFOLIO
14.3.5 RECENT DEVELOPMENTS
14.4 F. HOFFMAN-LA ROCHE LTD.
14.4.1 COMPANY SNAPSHOT
14.4.2 REVENUE ANALYSIS
14.4.3 COMPANY SHARE ANALYSIS
14.4.4 PRODUCT PORTFOLIO
14.4.5 RECENT DEVELOPMENTS
14.5 BRISTOL-MYERS SQUIBB COMPANY
14.5.1 COMPANY SNAPSHOT
14.5.2 REVENUE ANALYSIS
14.5.3 COMPANY SHARE ANALYSIS
14.5.4 PRODUCT PORTFOLIO
14.5.5 RECENT DEVELOPMENTS
14.6 ARROWHEAD PHARMACEUTICALS, INC.
14.6.1 COMPANY SNAPSHOT
14.6.2 REVENUE ANALYSIS
14.6.3 PRODUCT PORTFOLIO
14.6.4 RECENT DEVELOPMENTS
14.7 ARBUTUS BIOPHARMA
14.7.1 COMPANY SNAPSHOT
14.7.2 REVENUE ANALYSIS
14.7.3 PRODUCT PORTFOLIO
14.7.4 RECENT UPDATES
14.8 AUROBINDO PHARMA
14.8.1 COMPANY SNAPSHOT
14.8.2 REVENUE ANALYSIS
14.8.3 PRODUCT PORTFOLIO
14.8.4 RECENT UPDATES
14.9 LUPIN PHARMACEUTICALS, INC.
14.9.1 COMPANY SNAPSHOT
14.9.2 PRODUCT PORTFOLIO
14.9.3 RECENT UPDATES
14.1 MERCK & CO., INC.,
14.10.1 COMPANY SNAPSHOT
14.10.2 REVENUE ANALYSIS
14.10.3 PRODUCT PORTFOLIO
14.10.4 RECENT DEVELOPMENTS
14.11 NOVARTIS AG
14.11.1 COMPANY SNAPSHOT
14.11.2 REVENUE
14.11.3 PRODUCT PORTFOLIO
14.11.4 RECENT DEVELOPMENT
14.12 TEVA PHARMACEUTICAL INDUSTRIES
14.12.1 COMPANY SNAPSHOT
14.12.2 PRODUCT PORTFOLIO
14.12.3 RECENT DEVELOPMENTS
14.13 ZYDUS PHARMACEUTICALS, INC.
14.13.1 COMPANY SNAPSHOT
14.13.2 PRODUCT PORTFOLIO
14.13.3 REVENUE
14.13.4 RECENT DEVELOPMENT
15 QUESTIONNAIRE
16 RELATED REPORTS
Список таблиц
TABLE 1 GLOBAL CLINICAL TRIAL AND PIPELINE A-LYSIS AS PER THE COMPANY
TABLE 2 DISTRIBUTION OF PRODUCTS OR PROJECTS BY PHASE
TABLE 3 COUNTRY WISE EPIDEMIOLOGY FOR HEPATITIS B
TABLE 4 COST OF HEPATITIS B MEDICATIONS: BRAND VS. GENERIC PRICES
TABLE 5 GLOBAL HEPATITIS B INFECTION MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 6 GLOBAL CHRONIC IN HEPATITIS B INFECTION MARKET, BY REGION, 2022-2031 (USD MILLION)
TABLE 7 GLOBAL ACUTE IN HEPATITIS B INFECTION MARKET, BY REGION, 2022-2031 (USD MILLION)
TABLE 8 GLOBAL HEPATITIS B INFECTION MARKET, BY TREATMENT, 2022-2031 (USD MILLION)
TABLE 9 GLOBAL VACCINE IN HEPATITIS B INFECTION MARKET, BY REGION, 2022-2031 (USD MILLION)
TABLE 10 GLOBAL VACCINE, ANTIVIRAL DRUGS, IMMUNE MODULATOR DRUGS IN HEPATITIS B INFECTION MARKET, BY DISTRIBUTION CHANNEL, 2022-2031 (USD MILLION)
TABLE 11 GLOBAL ANTIVIRAL DRUGS IN HEPATITIS B INFECTION MARKET, BY REGION, 2022-2031 (USD MILLION)
TABLE 12 GLOBAL ANTIVIRAL DRUGS IN HEPATITIS B INFECTION MARKET, BY TREATMENT, 2022-2031 (USD MILLION)
TABLE 13 GLOBAL IMMUNE MODULATOR DRUGS IN HEPATITIS B INFECTION MARKET, BY REGION, 2022-2031 (USD MILLION)
TABLE 14 GLOBAL IMMUNE MODULATOR DRUGS IN HEPATITIS B INFECTION MARKET, BY TREATMENT, 2022-2031 (USD MILLION)
TABLE 15 GLOBAL SURGERY IN HEPATITIS B INFECTION MARKET, BY REGION, 2022-2031 (USD MILLION)
TABLE 16 GLOBAL HEPATITIS B INFECTION MARKET, BY REGION, 2022-2031 (USD MILLION)
TABLE 17 NORTH AMERICA HEPATITIS B INFECTION MARKET, BY COUNTRY, 2022-2031 (USD MILLION)
TABLE 18 NORTH AMERICA HEPATITIS B INFECTION MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 19 NORTH AMERICA HEPATITIS B INFECTION MARKET, BY TREATMENT, 2022-2031 (USD MILLION)
TABLE 20 NORTH AMERICA ANTIVIRAL DRUGS IN HEPATITIS B INFECTION MARKET, BY TREATMENT, 2022-2031 (USD MILLION)
TABLE 21 NORTH AMERICA IMMUNE MODULATOR DRUGS IN HEPATITIS B INFECTION MARKET, BY TREATMENT, 2022-2031 (USD MILLION)
TABLE 22 NORTH AMERICA VACCINE, ANTIVIRAL DRUGS, IMMUNE MODULATOR DRUGS IN HEPATITIS B INFECTION MARKET, BY DISTRIBUTION CHANNEL, 2022-2031 (USD MILLION)
TABLE 23 U.S. HEPATITIS B INFECTION MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 24 U.S. HEPATITIS B INFECTION MARKET, BY TREATMENT, 2022-2031 (USD MILLION)
TABLE 25 U.S. ANTIVIRAL DRUGS IN HEPATITIS B INFECTION MARKET, BY TREATMENT, 2022-2031 (USD MILLION)
TABLE 26 U.S. IMMUNE MODULATOR DRUGS IN HEPATITIS B INFECTION MARKET, BY TREATMENT, 2022-2031 (USD MILLION)
TABLE 27 U.S. VACCINE, ANTIVIRAL DRUGS, IMMUNE MODULATOR DRUGS IN HEPATITIS B INFECTION MARKET, BY DISTRIBUTION CHANNEL, 2022-2031 (USD MILLION)
TABLE 28 CANADA HEPATITIS B INFECTION MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 29 CANADA HEPATITIS B INFECTION MARKET, BY TREATMENT, 2022-2031 (USD MILLION)
TABLE 30 CANADA ANTIVIRAL DRUGS IN HEPATITIS B INFECTION MARKET, BY TREATMENT, 2022-2031 (USD MILLION)
TABLE 31 CANADA IMMUNE MODULATOR DRUGS IN HEPATITIS B INFECTION MARKET, BY TREATMENT, 2022-2031 (USD MILLION)
TABLE 32 CANADA VACCINE, ANTIVIRAL DRUGS, IMMUNE MODULATOR DRUGS IN HEPATITIS B INFECTION MARKET, BY DISTRIBUTION CHANNEL, 2022-2031 (USD MILLION)
TABLE 33 MEXICO HEPATITIS B INFECTION MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 34 MEXICO HEPATITIS B INFECTION MARKET, BY TREATMENT, 2022-2031 (USD MILLION)
TABLE 35 MEXICO ANTIVIRAL DRUGS IN HEPATITIS B INFECTION MARKET, BY TREATMENT, 2022-2031 (USD MILLION)
TABLE 36 MEXICO IMMUNE MODULATOR DRUGS IN HEPATITIS B INFECTION MARKET, BY TREATMENT, 2022-2031 (USD MILLION)
TABLE 37 MEXICO VACCINE, ANTIVIRAL DRUGS, IMMUNE MODULATOR DRUGS IN HEPATITIS B INFECTION MARKET, BY DISTRIBUTION CHANNEL, 2022-2031 (USD MILLION)
TABLE 38 SOUTH AMERICA HEPATITIS B INFECTION MARKET, BY COUNTRY, 2022-2031 (USD MILLION)
TABLE 39 SOUTH AMERICA HEPATITIS B INFECTION MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 40 SOUTH AMERICA HEPATITIS B INFECTION MARKET, BY TREATMENT, 2022-2031 (USD MILLION)
TABLE 41 SOUTH AMERICA ANTIVIRAL DRUGS IN HEPATITIS B INFECTION MARKET, BY TREATMENT, 2022-2031 (USD MILLION)
TABLE 42 SOUTH AMERICA IMMUNE MODULATOR DRUGS IN HEPATITIS B INFECTION MARKET, BY TREATMENT, 2022-2031 (USD MILLION)
TABLE 43 SOUTH AMERICA VACCINE, ANTIVIRAL DRUGS, IMMUNE MODULATOR DRUGS IN HEPATITIS B INFECTION MARKET, BY DISTRIBUTION CHANNEL, 2022-2031 (USD MILLION)
TABLE 44 BRAZIL HEPATITIS B INFECTION MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 45 BRAZIL HEPATITIS B INFECTION MARKET, BY TREATMENT, 2022-2031 (USD MILLION)
TABLE 46 BRAZIL ANTIVIRAL DRUGS IN HEPATITIS B INFECTION MARKET, BY TREATMENT, 2022-2031 (USD MILLION)
TABLE 47 BRAZIL IMMUNE MODULATOR DRUGS IN HEPATITIS B INFECTION MARKET, BY TREATMENT, 2022-2031 (USD MILLION)
TABLE 48 BRAZIL VACCINE, ANTIVIRAL DRUGS, IMMUNE MODULATOR DRUGS IN HEPATITIS B INFECTION MARKET, BY DISTRIBUTION CHANNEL, 2022-2031 (USD MILLION)
TABLE 49 ARGENTINA HEPATITIS B INFECTION MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 50 ARGENTINA HEPATITIS B INFECTION MARKET, BY TREATMENT, 2022-2031 (USD MILLION)
TABLE 51 ARGENTINA ANTIVIRAL DRUGS IN HEPATITIS B INFECTION MARKET, BY TREATMENT, 2022-2031 (USD MILLION)
TABLE 52 ARGENTINA IMMUNE MODULATOR DRUGS IN HEPATITIS B INFECTION MARKET, BY TREATMENT, 2022-2031 (USD MILLION)
TABLE 53 ARGENTINA VACCINE, ANTIVIRAL DRUGS, IMMUNE MODULATOR DRUGS IN HEPATITIS B INFECTION MARKET, BY DISTRIBUTION CHANNEL, 2022-2031 (USD MILLION)
TABLE 54 REST OF SOUTH AMERICA HEPATITIS B INFECTION MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 55 MIDDLE EAST AND AFRICA HEPATITIS B INFECTION MARKET, BY COUNTRY, 2022-2031 (USD MILLION)
TABLE 56 MIDDLE EAST AND AFRICA HEPATITIS B INFECTION MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 57 MIDDLE EAST AND AFRICA HEPATITIS B INFECTION MARKET, BY TREATMENT, 2022-2031 (USD MILLION)
TABLE 58 MIDDLE EAST AND AFRICA ANTIVIRAL DRUGS IN HEPATITIS B INFECTION MARKET, BY TREATMENT, 2022-2031 (USD MILLION)
TABLE 59 MIDDLE EAST AND AFRICA IMMUNE MODULATOR DRUGS IN HEPATITIS B INFECTION MARKET, BY TREATMENT, 2022-2031 (USD MILLION)
TABLE 60 MIDDLE EAST AND AFRICA VACCINE, ANTIVIRAL DRUGS, IMMUNE MODULATOR DRUGS IN HEPATITIS B INFECTION MARKET, BY DISTRIBUTION CHANNEL, 2022-2031 (USD MILLION)
TABLE 61 SOUTH AFRICA HEPATITIS B INFECTION MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 62 SOUTH AFRICA HEPATITIS B INFECTION MARKET, BY TREATMENT, 2022-2031 (USD MILLION)
TABLE 63 SOUTH AFRICA ANTIVIRAL DRUGS IN HEPATITIS B INFECTION MARKET, BY TREATMENT, 2022-2031 (USD MILLION)
TABLE 64 SOUTH AFRICA IMMUNE MODULATOR DRUGS IN HEPATITIS B INFECTION MARKET, BY TREATMENT, 2022-2031 (USD MILLION)
TABLE 65 SOUTH AFRICA VACCINE, ANTIVIRAL DRUGS, IMMUNE MODULATOR DRUGS IN HEPATITIS B INFECTION MARKET, BY DISTRIBUTION CHANNEL, 2022-2031 (USD MILLION)
TABLE 66 SAUDI ARABIA HEPATITIS B INFECTION MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 67 SAUDI ARABIA HEPATITIS B INFECTION MARKET, BY TREATMENT, 2022-2031 (USD MILLION)
TABLE 68 SAUDI ARABIA ANTIVIRAL DRUGS IN HEPATITIS B INFECTION MARKET, BY TREATMENT, 2022-2031 (USD MILLION)
TABLE 69 SAUDI ARABIA IMMUNE MODULATOR DRUGS IN HEPATITIS B INFECTION MARKET, BY TREATMENT, 2022-2031 (USD MILLION)
TABLE 70 SAUDI ARABIA VACCINE, ANTIVIRAL DRUGS, IMMUNE MODULATOR DRUGS IN HEPATITIS B INFECTION MARKET, BY DISTRIBUTION CHANNEL, 2022-2031 (USD MILLION)
TABLE 71 EGYPT HEPATITIS B INFECTION MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 72 EGYPT HEPATITIS B INFECTION MARKET, BY TREATMENT, 2022-2031 (USD MILLION)
TABLE 73 EGYPT ANTIVIRAL DRUGS IN HEPATITIS B INFECTION MARKET, BY TREATMENT, 2022-2031 (USD MILLION)
TABLE 74 EGYPT IMMUNE MODULATOR DRUGS IN HEPATITIS B INFECTION MARKET, BY TREATMENT, 2022-2031 (USD MILLION)
TABLE 75 EGYPT VACCINE, ANTIVIRAL DRUGS, IMMUNE MODULATOR DRUGS IN HEPATITIS B INFECTION MARKET, BY DISTRIBUTION CHANNEL, 2022-2031 (USD MILLION)
TABLE 76 KUWAIT HEPATITIS B INFECTION MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 77 KUWAIT HEPATITIS B INFECTION MARKET, BY TREATMENT, 2022-2031 (USD MILLION)
TABLE 78 KUWAIT ANTIVIRAL DRUGS IN HEPATITIS B INFECTION MARKET, BY TREATMENT, 2022-2031 (USD MILLION)
TABLE 79 KUWAIT IMMUNE MODULATOR DRUGS IN HEPATITIS B INFECTION MARKET, BY TREATMENT, 2022-2031 (USD MILLION)
TABLE 80 KUWAIT VACCINE, ANTIVIRAL DRUGS, IMMUNE MODULATOR DRUGS IN HEPATITIS B INFECTION MARKET, BY DISTRIBUTION CHANNEL, 2022-2031 (USD MILLION)
TABLE 81 QATAR HEPATITIS B INFECTION MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 82 QATAR HEPATITIS B INFECTION MARKET, BY TREATMENT, 2022-2031 (USD MILLION)
TABLE 83 QATAR ANTIVIRAL DRUGS IN HEPATITIS B INFECTION MARKET, BY TREATMENT, 2022-2031 (USD MILLION)
TABLE 84 QATAR IMMUNE MODULATOR DRUGS IN HEPATITIS B INFECTION MARKET, BY TREATMENT, 2022-2031 (USD MILLION)
TABLE 85 QATAR VACCINE, ANTIVIRAL DRUGS, IMMUNE MODULATOR DRUGS IN HEPATITIS B INFECTION MARKET, BY DISTRIBUTION CHANNEL, 2022-2031 (USD MILLION)
TABLE 86 U.A.E HEPATITIS B INFECTION MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 87 U.A.E HEPATITIS B INFECTION MARKET, BY TREATMENT, 2022-2031 (USD MILLION)
TABLE 88 U.A.E ANTIVIRAL DRUGS IN HEPATITIS B INFECTION MARKET, BY TREATMENT, 2022-2031 (USD MILLION)
TABLE 89 U.A.E IMMUNE MODULATOR DRUGS IN HEPATITIS B INFECTION MARKET, BY TREATMENT, 2022-2031 (USD MILLION)
TABLE 90 U.A.E VACCINE, ANTIVIRAL DRUGS, IMMUNE MODULATOR DRUGS IN HEPATITIS B INFECTION MARKET, BY DISTRIBUTION CHANNEL, 2022-2031 (USD MILLION)
TABLE 91 OMAN HEPATITIS B INFECTION MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 92 OMAN HEPATITIS B INFECTION MARKET, BY TREATMENT, 2022-2031 (USD MILLION)
TABLE 93 OMAN ANTIVIRAL DRUGS IN HEPATITIS B INFECTION MARKET, BY TREATMENT, 2022-2031 (USD MILLION)
TABLE 94 OMAN IMMUNE MODULATOR DRUGS IN HEPATITIS B INFECTION MARKET, BY TREATMENT, 2022-2031 (USD MILLION)
TABLE 95 OMAN VACCINE, ANTIVIRAL DRUGS, IMMUNE MODULATOR DRUGS IN HEPATITIS B INFECTION MARKET, BY DISTRIBUTION CHANNEL, 2022-2031 (USD MILLION)
TABLE 96 BAHRAIN HEPATITIS B INFECTION MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 97 BAHRAIN HEPATITIS B INFECTION MARKET, BY TREATMENT, 2022-2031 (USD MILLION)
TABLE 98 BAHRAIN ANTIVIRAL DRUGS IN HEPATITIS B INFECTION MARKET, BY TREATMENT, 2022-2031 (USD MILLION)
TABLE 99 BAHRAIN IMMUNE MODULATOR DRUGS IN HEPATITIS B INFECTION MARKET, BY TREATMENT, 2022-2031 (USD MILLION)
TABLE 100 BAHRAIN VACCINE, ANTIVIRAL DRUGS, IMMUNE MODULATOR DRUGS IN HEPATITIS B INFECTION MARKET, BY DISTRIBUTION CHANNEL, 2022-2031 (USD MILLION)
TABLE 101 REST OF MIDDLE EAST AND AFRICA HEPATITIS B INFECTION MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 102 ASIA-PACIFIC HEPATITIS B INFECTION MARKET, BY COUNTRY, 2022-2031 (USD MILLION)
TABLE 103 ASIA-PACIFIC HEPATITIS B INFECTION MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 104 ASIA-PACIFIC HEPATITIS B INFECTION MARKET, BY TREATMENT, 2022-2031 (USD MILLION)
TABLE 105 ASIA-PACIFIC ANTIVIRAL DRUGS IN HEPATITIS B INFECTION MARKET, BY TREATMENT, 2022-2031 (USD MILLION)
TABLE 106 ASIA-PACIFIC IMMUNE MODULATOR DRUGS IN HEPATITIS B INFECTION MARKET, BY TREATMENT, 2022-2031 (USD MILLION)
TABLE 107 CHINA VACCINE, ANTIVIRAL DRUGS, IMMUNE MODULATOR DRUGS IN HEPATITIS B INFECTION MARKET, BY DISTRIBUTION CHANNEL, 2022-2031 (USD MILLION)
TABLE 108 CHINA HEPATITIS B INFECTION MARKET, BY TREATMENT, 2022-2031 (USD MILLION)
TABLE 109 CHINA HEPATITIS B INFECTION MARKET, BY TREATMENT, 2022-2031 (USD MILLION)
TABLE 110 CHINA ANTIVIRAL DRUGS IN HEPATITIS B INFECTION MARKET, BY TREATMENT, 2022-2031 (USD MILLION)
TABLE 111 CHINA IMMUNE MODULATOR DRUGS IN HEPATITIS B INFECTION MARKET, BY TREATMENT, 2022-2031 (USD MILLION)
TABLE 112 CHINA VACCINE, ANTIVIRAL DRUGS, IMMUNE MODULATOR DRUGS IN HEPATITIS B INFECTION MARKET, BY DISTRIBUTION CHANNEL, 2022-2031 (USD MILLION)
TABLE 113 INDIA HEPATITIS B INFECTION MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 114 INDIA HEPATITIS B INFECTION MARKET, BY TREATMENT, 2022-2031 (USD MILLION)
TABLE 115 INDIA ANTIVIRAL DRUGS IN HEPATITIS B INFECTION MARKET, BY TREATMENT, 2022-2031 (USD MILLION)
TABLE 116 INDIA IMMUNE MODULATOR DRUGS IN HEPATITIS B INFECTION MARKET, BY TREATMENT, 2022-2031 (USD MILLION)
TABLE 117 INDIA VACCINE, ANTIVIRAL DRUGS, IMMUNE MODULATOR DRUGS IN HEPATITIS B INFECTION MARKET, BY DISTRIBUTION CHANNEL, 2022-2031 (USD MILLION)
TABLE 118 INDONESIA HEPATITIS B INFECTION MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 119 INDONESIA HEPATITIS B INFECTION MARKET, BY TREATMENT, 2022-2031 (USD MILLION)
TABLE 120 INDONESIA ANTIVIRAL DRUGS IN HEPATITIS B INFECTION MARKET, BY TREATMENT, 2022-2031 (USD MILLION)
TABLE 121 INDONESIA IMMUNE MODULATOR DRUGS IN HEPATITIS B INFECTION MARKET, BY TREATMENT, 2022-2031 (USD MILLION)
TABLE 122 INDONESIA VACCINE, ANTIVIRAL DRUGS, IMMUNE MODULATOR DRUGS IN HEPATITIS B INFECTION MARKET, BY DISTRIBUTION CHANNEL, 2022-2031 (USD MILLION)
TABLE 123 JAPAN HEPATITIS B INFECTION MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 124 JAPAN HEPATITIS B INFECTION MARKET, BY TREATMENT, 2022-2031 (USD MILLION)
TABLE 125 JAPAN ANTIVIRAL DRUGS IN HEPATITIS B INFECTION MARKET, BY TREATMENT, 2022-2031 (USD MILLION)
TABLE 126 JAPAN IMMUNE MODULATOR DRUGS IN HEPATITIS B INFECTION MARKET, BY TREATMENT, 2022-2031 (USD MILLION)
TABLE 127 JAPAN VACCINE, ANTIVIRAL DRUGS, IMMUNE MODULATOR DRUGS IN HEPATITIS B INFECTION MARKET, BY DISTRIBUTION CHANNEL, 2022-2031 (USD MILLION)
TABLE 128 VIETNAM HEPATITIS B INFECTION MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 129 VIETNAM HEPATITIS B INFECTION MARKET, BY TREATMENT, 2022-2031 (USD MILLION)
TABLE 130 VIETNAM ANTIVIRAL DRUGS IN HEPATITIS B INFECTION MARKET, BY TREATMENT, 2022-2031 (USD MILLION)
TABLE 131 VIETNAM IMMUNE MODULATOR DRUGS IN HEPATITIS B INFECTION MARKET, BY TREATMENT, 2022-2031 (USD MILLION)
TABLE 132 VIETNAM VACCINE, ANTIVIRAL DRUGS, IMMUNE MODULATOR DRUGS IN HEPATITIS B INFECTION MARKET, BY DISTRIBUTION CHANNEL, 2022-2031 (USD MILLION)
TABLE 133 PHILIPPINES HEPATITIS B INFECTION MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 134 PHILIPPINES HEPATITIS B INFECTION MARKET, BY TREATMENT, 2022-2031 (USD MILLION)
TABLE 135 PHILIPPINES ANTIVIRAL DRUGS IN HEPATITIS B INFECTION MARKET, BY TREATMENT, 2022-2031 (USD MILLION)
TABLE 136 PHILIPPINES IMMUNE MODULATOR DRUGS IN HEPATITIS B INFECTION MARKET, BY TREATMENT, 2022-2031 (USD MILLION)
TABLE 137 PHILIPPINES VACCINE, ANTIVIRAL DRUGS, IMMUNE MODULATOR DRUGS IN HEPATITIS B INFECTION MARKET, BY DISTRIBUTION CHANNEL, 2022-2031 (USD MILLION)
TABLE 138 THAILAND HEPATITIS B INFECTION MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 139 THAILAND HEPATITIS B INFECTION MARKET, BY TREATMENT, 2022-2031 (USD MILLION)
TABLE 140 THAILAND ANTIVIRAL DRUGS IN HEPATITIS B INFECTION MARKET, BY TREATMENT, 2022-2031 (USD MILLION)
TABLE 141 THAILAND IMMUNE MODULATOR DRUGS IN HEPATITIS B INFECTION MARKET, BY TREATMENT, 2022-2031 (USD MILLION)
TABLE 142 THAILAND VACCINE, ANTIVIRAL DRUGS, IMMUNE MODULATOR DRUGS IN HEPATITIS B INFECTION MARKET, BY DISTRIBUTION CHANNEL, 2022-2031 (USD MILLION)
TABLE 143 SOUTH KOREA HEPATITIS B INFECTION MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 144 SOUTH KOREA HEPATITIS B INFECTION MARKET, BY TREATMENT, 2022-2031 (USD MILLION)
TABLE 145 SOUTH KOREA ANTIVIRAL DRUGS IN HEPATITIS B INFECTION MARKET, BY TREATMENT, 2022-2031 (USD MILLION)
TABLE 146 SOUTH KOREA IMMUNE MODULATOR DRUGS IN HEPATITIS B INFECTION MARKET, BY TREATMENT, 2022-2031 (USD MILLION)
TABLE 147 SOUTH KOREA VACCINE, ANTIVIRAL DRUGS, IMMUNE MODULATOR DRUGS IN HEPATITIS B INFECTION MARKET, BY DISTRIBUTION CHANNEL, 2022-2031 (USD MILLION)
TABLE 148 AUSTRALIA HEPATITIS B INFECTION MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 149 AUSTRALIA HEPATITIS B INFECTION MARKET, BY TREATMENT, 2022-2031 (USD MILLION)
TABLE 150 AUSTRALIA ANTIVIRAL DRUGS IN HEPATITIS B INFECTION MARKET, BY TREATMENT, 2022-2031 (USD MILLION)
TABLE 151 AUSTRALIA IMMUNE MODULATOR DRUGS IN HEPATITIS B INFECTION MARKET, BY TREATMENT, 2022-2031 (USD MILLION)
TABLE 152 AUSTRALIA VACCINE, ANTIVIRAL DRUGS, IMMUNE MODULATOR DRUGS IN HEPATITIS B INFECTION MARKET, BY DISTRIBUTION CHANNEL, 2022-2031 (USD MILLION)
TABLE 153 SINGAPORE HEPATITIS B INFECTION MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 154 SINGAPORE HEPATITIS B INFECTION MARKET, BY TREATMENT, 2022-2031 (USD MILLION)
TABLE 155 SINGAPORE ANTIVIRAL DRUGS IN HEPATITIS B INFECTION MARKET, BY TREATMENT, 2022-2031 (USD MILLION)
TABLE 156 SINGAPORE IMMUNE MODULATOR DRUGS IN HEPATITIS B INFECTION MARKET, BY TREATMENT, 2022-2031 (USD MILLION)
TABLE 157 SINGAPORE VACCINE, ANTIVIRAL DRUGS, IMMUNE MODULATOR DRUGS IN HEPATITIS B INFECTION MARKET, BY DISTRIBUTION CHANNEL, 2022-2031 (USD MILLION)
TABLE 158 MALAYSIA HEPATITIS B INFECTION MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 159 MALAYSIA HEPATITIS B INFECTION MARKET, BY TREATMENT, 2022-2031 (USD MILLION)
TABLE 160 MALAYSIA ANTIVIRAL DRUGS IN HEPATITIS B INFECTION MARKET, BY TREATMENT, 2022-2031 (USD MILLION)
TABLE 161 MALAYSIA IMMUNE MODULATOR DRUGS IN HEPATITIS B INFECTION MARKET, BY TREATMENT, 2022-2031 (USD MILLION)
TABLE 162 MALAYSIA VACCINE, ANTIVIRAL DRUGS, IMMUNE MODULATOR DRUGS IN HEPATITIS B INFECTION MARKET, BY DISTRIBUTION CHANNEL, 2022-2031 (USD MILLION)
TABLE 163 NEW ZEALAND HEPATITIS B INFECTION MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 164 NEW ZEALAND HEPATITIS B INFECTION MARKET, BY TREATMENT, 2022-2031 (USD MILLION)
TABLE 165 NEW ZEALAND ANTIVIRAL DRUGS IN HEPATITIS B INFECTION MARKET, BY TREATMENT, 2022-2031 (USD MILLION)
TABLE 166 NEW ZEALAND IMMUNE MODULATOR DRUGS IN HEPATITIS B INFECTION MARKET, BY TREATMENT, 2022-2031 (USD MILLION)
TABLE 167 NEW ZEALAND VACCINE, ANTIVIRAL DRUGS, IMMUNE MODULATOR DRUGS IN HEPATITIS B INFECTION MARKET, BY DISTRIBUTION CHANNEL, 2022-2031 (USD MILLION)
TABLE 168 TAIWAN HEPATITIS B INFECTION MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 169 TAIWAN HEPATITIS B INFECTION MARKET, BY TREATMENT, 2022-2031 (USD MILLION)
TABLE 170 TAIWAN ANTIVIRAL DRUGS IN HEPATITIS B INFECTION MARKET, BY TREATMENT, 2022-2031 (USD MILLION)
TABLE 171 TAIWAN IMMUNE MODULATOR DRUGS IN HEPATITIS B INFECTION MARKET, BY TREATMENT, 2022-2031 (USD MILLION)
TABLE 172 TAIWAN VACCINE, ANTIVIRAL DRUGS, IMMUNE MODULATOR DRUGS IN HEPATITIS B INFECTION MARKET, BY DISTRIBUTION CHANNEL, 2022-2031 (USD MILLION)
TABLE 173 REST OF ASIA-PACIFIC HEPATITIS B INFECTION MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 174 EUROPE HEPATITIS B INFECTION MARKET, BY COUNTRY, 2022-2031 (USD MILLION)
TABLE 175 EUROPE HEPATITIS B INFECTION MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 176 EUROPE HEPATITIS B INFECTION MARKET, BY TREATMENT, 2022-2031 (USD MILLION)
TABLE 177 EUROPE ANTIVIRAL DRUGS IN HEPATITIS B INFECTION MARKET, BY TREATMENT, 2022-2031 (USD MILLION)
TABLE 178 EUROPE IMMUNE MODULATOR DRUGS IN HEPATITIS B INFECTION MARKET, BY TREATMENT, 2022-2031 (USD MILLION)
TABLE 179 EUROPE VACCINE, ANTIVIRAL DRUGS, IMMUNE MODULATOR DRUGS IN HEPATITIS B INFECTION MARKET, BY DISTRIBUTION CHANNEL, 2022-2031 (USD MILLION)
TABLE 180 GERMANY HEPATITIS B INFECTION MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 181 GERMANY HEPATITIS B INFECTION MARKET, BY TREATMENT, 2022-2031 (USD MILLION)
TABLE 182 GERMANY ANTIVIRAL DRUGS IN HEPATITIS B INFECTION MARKET, BY TREATMENT, 2022-2031 (USD MILLION)
TABLE 183 GERMANY IMMUNE MODULATOR DRUGS IN HEPATITIS B INFECTION MARKET, BY TREATMENT, 2022-2031 (USD MILLION)
TABLE 184 GERMANY VACCINE, ANTIVIRAL DRUGS, IMMUNE MODULATOR DRUGS IN HEPATITIS B INFECTION MARKET, BY DISTRIBUTION CHANNEL, 2022-2031 (USD MILLION)
TABLE 185 U.K. HEPATITIS B INFECTION MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 186 U.K. HEPATITIS B INFECTION MARKET, BY TREATMENT, 2022-2031 (USD MILLION)
TABLE 187 U.K. ANTIVIRAL DRUGS IN HEPATITIS B INFECTION MARKET, BY TREATMENT, 2022-2031 (USD MILLION)
TABLE 188 U.K. IMMUNE MODULATOR DRUGS IN HEPATITIS B INFECTION MARKET, BY TREATMENT, 2022-2031 (USD MILLION)
TABLE 189 U.K. IMMUNE MODULATOR DRUGS IN HEPATITIS B INFECTION MARKET, BY TREATMENT, 2022-2031 (USD MILLION)
TABLE 190 TURKEY HEPATITIS B INFECTION MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 191 TURKEY HEPATITIS B INFECTION MARKET, BY TREATMENT, 2022-2031 (USD MILLION)
TABLE 192 TURKEY ANTIVIRAL DRUGS IN HEPATITIS B INFECTION MARKET, BY TREATMENT, 2022-2031 (USD MILLION)
TABLE 193 TURKEY IMMUNE MODULATOR DRUGS IN HEPATITIS B INFECTION MARKET, BY TREATMENT, 2022-2031 (USD MILLION)
TABLE 194 TURKEY VACCINE, ANTIVIRAL DRUGS, IMMUNE MODULATOR DRUGS IN HEPATITIS B INFECTION MARKET, BY DISTRIBUTION CHANNEL, 2022-2031 (USD MILLION)
TABLE 195 RUSSIA HEPATITIS B INFECTION MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 196 RUSSIA HEPATITIS B INFECTION MARKET, BY TREATMENT, 2022-2031 (USD MILLION)
TABLE 197 RUSSIA ANTIVIRAL DRUGS IN HEPATITIS B INFECTION MARKET, BY TREATMENT, 2022-2031 (USD MILLION)
TABLE 198 RUSSIA IMMUNE MODULATOR DRUGS IN HEPATITIS B INFECTION MARKET, BY TREATMENT, 2022-2031 (USD MILLION)
TABLE 199 RUSSIA VACCINE, ANTIVIRAL DRUGS, IMMUNE MODULATOR DRUGS IN HEPATITIS B INFECTION MARKET, BY DISTRIBUTION CHANNEL, 2022-2031 (USD MILLION)
TABLE 200 SPAIN HEPATITIS B INFECTION MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 201 SPAIN HEPATITIS B INFECTION MARKET, BY TREATMENT, 2022-2031 (USD MILLION)
TABLE 202 SPAIN ANTIVIRAL DRUGS IN HEPATITIS B INFECTION MARKET, BY TREATMENT, 2022-2031 (USD MILLION)
TABLE 203 SPAIN IMMUNE MODULATOR DRUGS IN HEPATITIS B INFECTION MARKET, BY TREATMENT, 2022-2031 (USD MILLION)
TABLE 204 SPAIN VACCINE, ANTIVIRAL DRUGS, IMMUNE MODULATOR DRUGS IN HEPATITIS B INFECTION MARKET, BY DISTRIBUTION CHANNEL, 2022-2031 (USD MILLION)
TABLE 205 ITALY HEPATITIS B INFECTION MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 206 ITALY HEPATITIS B INFECTION MARKET, BY TREATMENT, 2022-2031 (USD MILLION)
TABLE 207 ITALY ANTIVIRAL DRUGS IN HEPATITIS B INFECTION MARKET, BY TREATMENT, 2022-2031 (USD MILLION)
TABLE 208 ITALY IMMUNE MODULATOR DRUGS IN HEPATITIS B INFECTION MARKET, BY TREATMENT, 2022-2031 (USD MILLION)
TABLE 209 ITALY VACCINE, ANTIVIRAL DRUGS, IMMUNE MODULATOR DRUGS IN HEPATITIS B INFECTION MARKET, BY DISTRIBUTION CHANNEL, 2022-2031 (USD MILLION)
TABLE 210 SWEDEN HEPATITIS B INFECTION MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 211 SWEDEN HEPATITIS B INFECTION MARKET, BY TREATMENT, 2022-2031 (USD MILLION)
TABLE 212 SWEDEN ANTIVIRAL DRUGS IN HEPATITIS B INFECTION MARKET, BY TREATMENT, 2022-2031 (USD MILLION)
TABLE 213 SWEDEN IMMUNE MODULATOR DRUGS IN HEPATITIS B INFECTION MARKET, BY TREATMENT, 2022-2031 (USD MILLION)
TABLE 214 SWEDEN VACCINE, ANTIVIRAL DRUGS, IMMUNE MODULATOR DRUGS IN HEPATITIS B INFECTION MARKET, BY DISTRIBUTION CHANNEL, 2022-2031 (USD MILLION)
TABLE 215 BELGIUM HEPATITIS B INFECTION MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 216 BELGIUM HEPATITIS B INFECTION MARKET, BY TREATMENT, 2022-2031 (USD MILLION)
TABLE 217 BELGIUM ANTIVIRAL DRUGS IN HEPATITIS B INFECTION MARKET, BY TREATMENT, 2022-2031 (USD MILLION)
TABLE 218 BELGIUM IMMUNE MODULATOR DRUGS IN HEPATITIS B INFECTION MARKET, BY TREATMENT, 2022-2031 (USD MILLION)
TABLE 219 BELGIUM VACCINE, ANTIVIRAL DRUGS, IMMUNE MODULATOR DRUGS IN HEPATITIS B INFECTION MARKET, BY DISTRIBUTION CHANNEL, 2022-2031 (USD MILLION)
TABLE 220 POLAND HEPATITIS B INFECTION MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 221 POLAND HEPATITIS B INFECTION MARKET, BY TREATMENT, 2022-2031 (USD MILLION)
TABLE 222 POLAND ANTIVIRAL DRUGS IN HEPATITIS B INFECTION MARKET, BY TREATMENT, 2022-2031 (USD MILLION)
TABLE 223 POLAND IMMUNE MODULATOR DRUGS IN HEPATITIS B INFECTION MARKET, BY TREATMENT, 2022-2031 (USD MILLION)
TABLE 224 POLAND VACCINE, ANTIVIRAL DRUGS, IMMUNE MODULATOR DRUGS IN HEPATITIS B INFECTION MARKET, BY DISTRIBUTION CHANNEL, 2022-2031 (USD MILLION)
TABLE 225 FRANCE HEPATITIS B INFECTION MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 226 FRANCE HEPATITIS B INFECTION MARKET, BY TREATMENT, 2022-2031 (USD MILLION)
TABLE 227 FRANCE ANTIVIRAL DRUGS IN HEPATITIS B INFECTION MARKET, BY TREATMENT, 2022-2031 (USD MILLION)
TABLE 228 FRANCE IMMUNE MODULATOR DRUGS IN HEPATITIS B INFECTION MARKET, BY TREATMENT, 2022-2031 (USD MILLION)
TABLE 229 FRANCE VACCINE, ANTIVIRAL DRUGS, IMMUNE MODULATOR DRUGS IN HEPATITIS B INFECTION MARKET, BY DISTRIBUTION CHANNEL, 2022-2031 (USD MILLION)
TABLE 230 SWITZERLAND HEPATITIS B INFECTION MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 231 SWITZERLAND HEPATITIS B INFECTION MARKET, BY TREATMENT, 2022-2031 (USD MILLION)
TABLE 232 SWITZERLAND ANTIVIRAL DRUGS IN HEPATITIS B INFECTION MARKET, BY TREATMENT, 2022-2031 (USD MILLION)
TABLE 233 SWITZERLAND IMMUNE MODULATOR DRUGS IN HEPATITIS B INFECTION MARKET, BY TREATMENT, 2022-2031 (USD MILLION)
TABLE 234 SWITZERLAND VACCINE, ANTIVIRAL DRUGS, IMMUNE MODULATOR DRUGS IN HEPATITIS B INFECTION MARKET, BY DISTRIBUTION CHANNEL, 2022-2031 (USD MILLION)
TABLE 235 NETHERLANDS HEPATITIS B INFECTION MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 236 NETHERLANDS HEPATITIS B INFECTION MARKET, BY TREATMENT, 2022-2031 (USD MILLION)
TABLE 237 NETHERLANDS ANTIVIRAL DRUGS IN HEPATITIS B INFECTION MARKET, BY TREATMENT, 2022-2031 (USD MILLION)
TABLE 238 NETHERLANDS IMMUNE MODULATOR DRUGS IN HEPATITIS B INFECTION MARKET, BY TREATMENT, 2022-2031 (USD MILLION)
TABLE 239 NETHERLANDS VACCINE, ANTIVIRAL DRUGS, IMMUNE MODULATOR DRUGS IN HEPATITIS B INFECTION MARKET, BY DISTRIBUTION CHANNEL, 2022-2031 (USD MILLION)
TABLE 240 NORWAY HEPATITIS B INFECTION MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 241 NORWAY HEPATITIS B INFECTION MARKET, BY TREATMENT, 2022-2031 (USD MILLION)
TABLE 242 NORWAY HEPATITIS B INFECTION MARKET, BY TREATMENT, 2022-2031 (USD MILLION)
TABLE 243 NORWAY IMMUNE MODULATOR DRUGS IN HEPATITIS B INFECTION MARKET, BY TREATMENT, 2022-2031 (USD MILLION)
TABLE 244 NORWAY VACCINE, ANTIVIRAL DRUGS, IMMUNE MODULATOR DRUGS IN HEPATITIS B INFECTION MARKET, BY DISTRIBUTION CHANNEL, 2022-2031 (USD MILLION)
TABLE 245 DENMARK HEPATITIS B INFECTION MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 246 DENMARK HEPATITIS B INFECTION MARKET, BY TREATMENT, 2022-2031 (USD MILLION)
TABLE 247 DENMARK ANTIVIRAL DRUGS IN HEPATITIS B INFECTION MARKET, BY TREATMENT, 2022-2031 (USD MILLION)
TABLE 248 DENMARK IMMUNE MODULATOR DRUGS IN HEPATITIS B INFECTION MARKET, BY TREATMENT, 2022-2031 (USD MILLION)
TABLE 249 DENMARK VACCINE, ANTIVIRAL DRUGS, IMMUNE MODULATOR DRUGS IN HEPATITIS B INFECTION MARKET, BY DISTRIBUTION CHANNEL, 2022-2031 (USD MILLION)
TABLE 250 FINLAND HEPATITIS B INFECTION MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 251 FINLAND HEPATITIS B INFECTION MARKET, BY TREATMENT, 2022-2031 (USD MILLION)
TABLE 252 FINLAND ANTIVIRAL DRUGS IN HEPATITIS B INFECTION MARKET, BY TREATMENT, 2022-2031 (USD MILLION)
TABLE 253 FINLAND IMMUNE MODULATOR DRUGS IN HEPATITIS B INFECTION MARKET, BY TREATMENT, 2022-2031 (USD MILLION)
TABLE 254 FINLAND VACCINE, ANTIVIRAL DRUGS, IMMUNE MODULATOR DRUGS IN HEPATITIS B INFECTION MARKET, BY DISTRIBUTION CHANNEL, 2022-2031 (USD MILLION)
TABLE 255 REST OF EUROPE HEPATITIS B INFECTION MARKET, BY TYPE, 2022-2031 (USD MILLION)
Список рисунков
FIGURE 1 GLOBAL HEPATITIS B INFECTION MARKET: SEGMENTATION
FIGURE 2 GLOBAL HEPATITIS B INFECTION MARKET: DATA TRIANGULATION
FIGURE 3 GLOBAL HEPATITIS B INFECTION MARKET: DROC ANALYSIS
FIGURE 4 GLOBAL HEPATITIS B INFECTION MARKET: GLOBAL VS REGIONAL MARKET ANALYSIS
FIGURE 5 GLOBAL HEPATITIS B INFECTION MARKET: COMPANY RESEARCH ANALYSIS
FIGURE 6 GLOBAL HEPATITIS B INFECTION MARKET: MULTIVARIATE MODELLING
FIGURE 7 GLOBAL HEPATITIS B INFECTION MARKET: INTERVIEW DEMOGRAPHICS
FIGURE 8 GLOBAL HEPATITIS B INFECTION MARKET: DBMR MARKET POSITION GRID
FIGURE 9 GLOBAL HEPATITIS B INFECTION MARKET: VENDOR SHARE ANALYSIS
FIGURE 10 GLOBAL HEPATITIS B INFECTION MARKET: SEGMENTATION
FIGURE 11 ASIA PACIFIC IS EXPECTED TO DOMINATE THE GLOBAL HEPATITIS B INFECTION MARKET AND IS EXPECTED TO GROW WITH THE HIGHEST CAGR IN THE FORECAST PERIOD OF 2024 TO 2031
FIGURE 12 TWO SEGMENTS COMPRISE THE GLOBAL HEPATITIS B INFECTION MARKET, BY TYPE
FIGURE 13 EXECUTIVE SUMMARY
FIGURE 14 STRATEGIC DECISIONS
FIGURE 15 GLOBAL HEPATITIS B INFECTION MARKET
FIGURE 16 CHRONIC SEGMENT IS EXPECTED TO ACCOUNT FOR THE LARGEST SHARE OF THE GLOBAL HEPATITIS B INFECTION MARKET IN 2024 & 2031
FIGURE 17 ASIA PACIFIC IS THE FASTEST GROWING MARKET FOR THE GLOBAL HEPATITIS B INFECTION MARKET IN 2024 & 2031
FIGURE 18 DROC ANALYSIS
FIGURE 19 BURDEN OF HBV INFECTION IN THE GENERAL POPULATION BY WHO REGION, 2019
FIGURE 20 GLOBAL HEPATITIS B INFECTION MARKET: BY TYPE, 2023
FIGURE 21 GLOBAL HEPATITIS B INFECTION MARKET: BY TYPE, 2024-2031 (USD MILLION)
FIGURE 22 GLOBAL HEPATITIS B INFECTION MARKET: BY TYPE, CAGR (2024-2031)
FIGURE 23 GLOBAL HEPATITIS B INFECTION MARKET: BY TYPE, LIFELINE CURVE
FIGURE 24 GLOBAL HEPATITIS B INFECTION MARKET: BY TREATMENT, 2023
FIGURE 25 GLOBAL HEPATITIS B INFECTION MARKET: BY TREATMENT, 2024-2031 (USD MILLION)
FIGURE 26 GLOBAL HEPATITIS B INFECTION MARKET: BY TREATMENT, CAGR (2024-2031)
FIGURE 27 GLOBAL HEPATITIS B INFECTION MARKET BY TREATMENT, LIFELINE CURVE
FIGURE 28 GLOBAL HEPATITIS B INFECTION MARKET, SNAPSHOT
FIGURE 29 GLOBAL HEPATITIS B TREATMENT MARKET: COMPANY SHARE 2023 (%)
FIGURE 30 NORTH AMERICA HEPATITIS B TREATMENT MARKET: COMPANY SHARE 2023 (%)
FIGURE 31 EUROPE HEPATITIS B TREATMENT MARKET: COMPANY SHARE 2023 (%)
FIGURE 32 ASIA-PACIFIC HEPATITIS B TREATMENT MARKET: COMPANY SHARE 2023 (%)
Методология исследования
Сбор данных и анализ базового года выполняются с использованием модулей сбора данных с большими размерами выборки. Этап включает получение рыночной информации или связанных данных из различных источников и стратегий. Он включает изучение и планирование всех данных, полученных из прошлого заранее. Он также охватывает изучение несоответствий информации, наблюдаемых в различных источниках информации. Рыночные данные анализируются и оцениваются с использованием статистических и последовательных моделей рынка. Кроме того, анализ доли рынка и анализ ключевых тенденций являются основными факторами успеха в отчете о рынке. Чтобы узнать больше, пожалуйста, запросите звонок аналитика или оставьте свой запрос.
Ключевой методологией исследования, используемой исследовательской группой DBMR, является триангуляция данных, которая включает в себя интеллектуальный анализ данных, анализ влияния переменных данных на рынок и первичную (отраслевую экспертную) проверку. Модели данных включают сетку позиционирования поставщиков, анализ временной линии рынка, обзор рынка и руководство, сетку позиционирования компании, патентный анализ, анализ цен, анализ доли рынка компании, стандарты измерения, глобальный и региональный анализ и анализ доли поставщика. Чтобы узнать больше о методологии исследования, отправьте запрос, чтобы поговорить с нашими отраслевыми экспертами.
Доступна настройка
Data Bridge Market Research является лидером в области передовых формативных исследований. Мы гордимся тем, что предоставляем нашим существующим и новым клиентам данные и анализ, которые соответствуют и подходят их целям. Отчет можно настроить, включив в него анализ ценовых тенденций целевых брендов, понимание рынка для дополнительных стран (запросите список стран), данные о результатах клинических испытаний, обзор литературы, обновленный анализ рынка и продуктовой базы. Анализ рынка целевых конкурентов можно проанализировать от анализа на основе технологий до стратегий портфеля рынка. Мы можем добавить столько конкурентов, о которых вам нужны данные в нужном вам формате и стиле данных. Наша команда аналитиков также может предоставить вам данные в сырых файлах Excel, сводных таблицах (книга фактов) или помочь вам в создании презентаций из наборов данных, доступных в отчете.
